Unfortunately, adecatumumab treatment did not show an impact on objective tumour regression in EpCAM overexpressing metastatic breast cancer patients [115], highlighting the need for further investigations of this agent in patients with EpCAM-overexpressing tumours. This evidence concerns the gene EPCAM and breast carcinoma.